Duan Wenzhen, Guo Zhihong, Jiang Haiyang, Ladenheim Bruce, Xu Xiangru, Cadet Jean Lud, Mattson Mark P
Laboratory of Neurosciences, National Institute on Aging Intramural Research Program, NIH, Baltimore, MD 21224, USA.
Ann Neurol. 2004 Apr;55(4):590-4. doi: 10.1002/ana.20075.
We report that administration of paroxetine, a widely prescribed antidepressant drug that acts by inhibiting reuptake of the neurotransmitter serotonin, suppresses the neurodegenerative process and increases the survival of huntingtin mutant mice, an animal model of Huntington's disease (HD). Paroxetine attenuated motor dysfunction and body weight loss and improved glucose metabolism in the HD mice. Paroxetine was beneficial when treatment was initiated before or after the onset of motor dysfunction, suggesting a potential for such antidepressant drugs in the treatment of presymptomatic and symptomatic HD patients.
我们报告称，帕罗西汀（一种广泛使用的抗抑郁药物，其作用机制是抑制神经递质血清素的再摄取）的给药可抑制神经退行性过程，并提高亨廷顿蛋白突变小鼠（亨廷顿舞蹈症（HD）的动物模型）的存活率。帕罗西汀减轻了HD小鼠的运动功能障碍和体重减轻，并改善了其葡萄糖代谢。在运动功能障碍发作之前或之后开始治疗时，帕罗西汀均有益处，这表明此类抗抑郁药物在治疗症状前和有症状的HD患者方面具有潜力。
